AML patients carrying NPM1, but not FLT3-ITD mutation (favourable risk group) were characterized by longer telomeres as compared to AML patients of the adverse risk group (with FLT3-ITD mutation and NPM1 wild-type). This evidence concerns the gene NPM1 and acute myeloid leukemia.